Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03110822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03110822 · ClinicalTrials.gov record · last posted 2023-11-01

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Name: A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients — clinical trial record (NCT03110822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorOncotherapeutics

Started2017-02-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated November 1, 2023 (before its estimated September 2024 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

Amendment record 9 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 9 times since 2017-04-06; most recent amendment 2023-10-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT03110822
Lead Sponsor	Oncotherapeutics Collaborators: Incyte Corporation
Conditions	Multiple Myeloma
Enrollment	134 participants
Start Date	2017-02-01
Primary Completion	2024-09 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2023-11-01